Technical Analysis for AADI - Aadi Biosciences, Inc.

Grade Last Price % Change Price Change
B 31.86 -1.45% -0.47
AADI closed down 1.45 percent on Friday, September 24, 2021, on 46 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical AADI trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
MACD Bullish Centerline Cross Bullish -1.45%
Wide Bands Range Expansion -1.45%
Overbought Stochastic Strength -1.45%
Crossed Above 50 DMA Bullish -2.45%
Expansion Pivot Buy Setup Bullish Swing Setup -2.45%
Pocket Pivot Bullish Swing Setup -2.45%
Multiple of Ten Bullish Other -2.45%
Wide Bands Range Expansion -2.45%
Older End-of-Day Signals for AADI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 13 hours ago
60 Minute Opening Range Breakdown about 13 hours ago
Possible Inside Day about 14 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Up 1% about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Aadi is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. Aadi’s lead product is FYARRO (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models.

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Disease Oncology Tumor Drug Delivery Antineoplastic Drugs Signal Transduction mTOR Mtor Inhibitors

Is AADI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 49.8
52 Week Low 14.3115
Average Volume 97,230
200-Day Moving Average 24.91
50-Day Moving Average 30.42
20-Day Moving Average 28.77
10-Day Moving Average 29.76
Average True Range 1.87
ADX 34.94
+DI 31.84
-DI 15.84
Chandelier Exit (Long, 3 ATRs) 28.88
Chandelier Exit (Short, 3 ATRs) 30.06
Upper Bollinger Bands 32.95
Lower Bollinger Band 24.59
Percent B (%b) 0.87
BandWidth 29.05
MACD Line 0.28
MACD Signal Line -0.29
MACD Histogram 0.5731
Fundamentals Value
Market Cap 1.5 Billion
Num Shares 47.1 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -115.85
Price-to-Sales 4.81
Price-to-Book 1.74
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.91
Resistance 3 (R3) 34.02 33.44 33.57
Resistance 2 (R2) 33.44 32.92 33.39 33.45
Resistance 1 (R1) 32.65 32.60 32.36 32.54 33.34
Pivot Point 32.08 32.08 31.93 32.02 32.08
Support 1 (S1) 31.29 31.55 31.00 31.18 30.38
Support 2 (S2) 30.71 31.23 30.66 30.27
Support 3 (S3) 29.92 30.71 30.15
Support 4 (S4) 29.81